• ACE2 review
• • Hamming I et al. The emerging role of ACE2 in physiology and disease. J Pathol 212: 1-11 (2007)
• ACE2 and ARDS
• • G Santacruz JF et al. Update in ARDS management: recent randomized controlled trials that changed our practice. Cleve Clin J Med. 73, 217 (2006)
  • Rubenfeld GD et al., Incidence and Outcomes of Acute Lung Injury. New England Journal of Medicine 16:1685 (2005)
  • Imai, Y. et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 436, 112-116 (2005).
  • Kuba, K. et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med 11, 875-879 (2005).
  • Kuba K, Penninger J et al. Angiotensin-converting enzyme 2 in lung diseases. Curr Opin Pharmacol. 6, 271-6 (2006)
  • Imai Y, Kuba K, Penninger J. The renin-angiotensin system in acute respiratory distress syndrome. Drug Discovery Today: Disease Mechanisms: Immuno-disorders and autoimmunity Vol. 3, No. 2 (2006)
• ACE2 and cardiovascular disease
• • Crackower, M.A. et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 417, 822-828 (2002)
  • Danilczyk, U. & Penninger, J.M. Angiotensin-converting enzyme II in the heart and the kidney. Circ Res 98, 463-471 (2006)
  • Sarkissian SD et al. ACE2: A novel therapeutic target for cardiovascular diseases. Progress in Biophysics and Molecular Biology 91, 163-98 (2006)
  • Ferrario CM. Angiotensin-Converting Enzyme 2 and Angiotensin-(1-7): An Evolving Story in Cardiovascular Regulation. Hypertension 47: 515-521 (2006)
  • Burrell LM et al. Myocardial infarction increases ACE2 expression in rat and humans. European Heart Journal 26: 369-375 (2005)
  • Goulter A et al. ACE2 gene expression is up-regulated in the human failing heart. BMC Medicine 2:19 (2004)
  • Huentelman M et al. Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. Exp Physiol 90.5, 783-790 (2005)
  • Yamamoto, K. et al. Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II. Hypertension 47, 718-726 (2006)
• ACE2 and kidney disease
• • Ingelfinger, J.R. ACE2: a new target for prevention of diabetic nephropathy? J Am Soc Nephrol 17, 2957-2959 (2006)
  • Danilczyk, U. & Penninger, J.M. Angiotensin-converting enzyme II in the heart and the kidney. Circ Res 98, 463-471 (2006)
  • Ye, M. et al. Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensin-converting enzyme: implications for albuminuria in diabetes. J Am Soc Nephrol 17, 3067-3075 (2006)
  • Soler MJ et al. ACE2 inhibition worsens glomular injury associated with increased ACE expression in streptozotocin-induced diabetic mice. Kidney International advance online publication, 20 June 2007
  • Reich H et al. Glomerular and Tubular Expression of ACE2 in Type 2 Diabetic Patients with Diabetic Nephropathy, submitted.
• APN01 publications based on Apeiron's work
• • Angiotensin-converting-enzyme 2 inhibits liver fibrosis in mice.
    Hepatology 2009
  • Targeting the Degradation of Angiotensin II With Recombinant Angiotensin-Convertng Enzyme 2. Prevention of Angiotensin II-Dependent Hypertension.
    Hypertension 2009
  • Human recombinant angiotensin converting enzyme 2 reduces the progression of diabetic nephropathy.
    Diabetes 2010
  • Recombinant angiotensin-converting enzyme 2 improves pulmonary blood flow and oxygenation in lipopolysaccharide-induced lung injury in piglets.
    Crit Care Med 2009
  • Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction Circulation. 2010